TABLE 4

The contribution of lymphatically transported TU to the total systemic exposure of T following postprandial oral administration of 80 mg of TU as either Andriol or Andriol Testocaps


Formulation

Dog Number

Testosterone Undecanoate

Testosterone

Percentage of Contribution of Lymphatically Transported TU to the AUCtotal for T
AUClymph deriveda
AUClymph derived
AUCmeasured
AUCtotal
nM·min nM·min nM·min nM·min
Andriol 2 22,217 2,016 493 2,509 80.3
4 22,067 4,035 792 4,827 83.6
5 36,330 4,516 968 5,474 82.4
7 19,338 4,054 550 4,604 88.1
Mean ± S.E. 24,988 ± 3,838 3,655 ± 558 701 ± 110 4,354 ± 642 83.6 ± 1.6b
Andriol Testocaps 1 14,650 2,544 239 2,787 91.4
3 26,025 4,652 246 4,898 95.0
6 7,696 1,073 723 1,796 59.7
8 46,321 6,453 677 7,130 90.5

Mean ± S.E.
23,673 ± 8,442
3,681 ± 1,180
471 ± 132
4,153 ± 1,185
84.1 ± 8.2b
  • a The AUClymph derived value for TU was used to determine the AUClymph derived value for T according to eq. 4.

  • b No significant difference (p > 0.05) in any parameter between Andriol and Andriol Testocaps.